| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.8 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | 0.0082 | 0.8 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |